Antagonists of IL-6 to raise albumin and/or lower CRP
First Claim
1. A method of improving survivability or quality of life of a patient in need thereof having elevated C-reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein the variable light chain of said antibody comprises the CDR 1 sequence of SEQ ID NO:
- 4, the CDR 2 sequence of SEQ ID NO;
5, and the CDR 3 sequence of SEQ ID NO;
6, and the variable heavy chain of said antibody comprises the CDR 1 sequence of SEQ ID NO;
7, the CDR 2 sequence of SEQ ID NO;
8 or 120, and the CDR 3 sequence of SEQ ID NO;
9, and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) is reduced, and whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
13 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient'"'"'s Glasgow Prognostic Score will be increased and survivability will preferably be improved.
137 Citations
29 Claims
-
1. A method of improving survivability or quality of life of a patient in need thereof having elevated C-reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein the variable light chain of said antibody comprises the CDR 1 sequence of SEQ ID NO:
- 4, the CDR 2 sequence of SEQ ID NO;
5, and the CDR 3 sequence of SEQ ID NO;
6, and the variable heavy chain of said antibody comprises the CDR 1 sequence of SEQ ID NO;
7, the CDR 2 sequence of SEQ ID NO;
8 or 120, and the CDR 3 sequence of SEQ ID NO;
9, and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) is reduced, and whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 20, 21, 22, 23, 24, 25)
- 4, the CDR 2 sequence of SEQ ID NO;
-
2. A method of improving survivability or quality of life of a patient in need thereof having reduced serum albumin levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment wherein the variable light chain of said antibody comprises the CDR 1 sequence of SEQ ID NO:
- 4, the CDR 2 sequence of SEQ ID NO;
5, and the CDR 3 sequence of SEQ ID NO;
6, and the variable heavy chain of said antibody comprises the CDR 1 sequence of SEQ ID NO;
7, the CDR 2 sequence of SEQ ID NO;
8 or 120, and the CDR 3 sequence of SEQ ID NO;
9, and whereby the patient'"'"'s serum albumin level is increased, whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
- 4, the CDR 2 sequence of SEQ ID NO;
-
3. A method of improving survivability or quality of life of a patient in need thereof having increased C reactive protein and reduced serum albumin levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein the variable light chain of said antibody comprises the CDR 1 sequence of SEQ ID NO:
- 4, the CDR 2 sequence of SEQ ID NO;
5, and the CDR 3 sequence of SEQ ID NO;
6, and the variable heavy chain of said antibody comprises the CDR 1 sequence of SEQ ID NO;
7, the CDR 2 sequence of SEQ ID NO;
8 or 120, and the CDR 3 sequence of SEQ ID NO;
9, and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) level is reduced and the patient'"'"'s serum albumin level is increased, and whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient. - View Dependent Claims (18, 19)
- 4, the CDR 2 sequence of SEQ ID NO;
-
4. A method of improving survivability or quality of life of a patient in need thereof having elevated C reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises the variable light chain sequence of SEQ ID NO:
- 2, or SEQ ID NO;
20, and the variable heavy chain of said antibody comprises the variable heavy chain sequence in SEQ ID NO;
3 or SEQ ID NO;
18 or 19, and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) level is reduced, and whereby the administration of the anti-IL-6 antibody results in improved survivability or quality if life in said patient.
- 2, or SEQ ID NO;
-
5. A method of improving survivability or quality of life of a patient in need thereof having reduced serum albumin levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises the variable light chain sequence of SEQ ID NO:
- 2, or SEQ ID NO;
20 and the variable heavy chain sequence of SEQ ID NO;
3, SEQ ID NO;
18 or SEQ ID NO;
19, and whereby the patient'"'"'s serum albumin level is increased, and whereby the administration of the anti-IL-6 antibody results in improved survivability or quality of life in said patient.
- 2, or SEQ ID NO;
-
6. A method of improving survivability or quality of life of a patient in need thereof having reduced serum albumin levels and increased C reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises the variable heavy chain sequence of SEQ ID NO:
- 18 or SEQ ID NO;
19 and the variable light chain sequence of SEQ ID NO;
20, and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) level is reduced and the patient'"'"'s serum albumin level is increased, whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
- 18 or SEQ ID NO;
-
7. A method of improving survivability or quality of life of a patient in need thereof having reduced serum albumin levels and increased C reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises a variable light sequence which is at least 95% identical to the variable light chain sequence of SEQ ID NO:
- 20 and a variable heavy chain sequence which is at least 95% identical to SEQ ID NO;
18 or 19 and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) level is reduced and the patient'"'"'s serum albumin level is increased.
- 20 and a variable heavy chain sequence which is at least 95% identical to SEQ ID NO;
-
26. A method of improving survivability or quality of life of a patient in need thereof having reduced serum albumin levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises the variable heavy chain sequence of SEQ ID NO:
- 18 or SEQ ID NO;
19 and the variable light chain sequence of SEQ ID NO;
20, and whereby the patient'"'"'s serum albumin level is increased, whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
- 18 or SEQ ID NO;
-
27. A method of improving survivability or quality of life of a patient in need thereof having increased C reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises the variable light chain sequence of SEQ ID NO:
- 18, or SEQ ID NO;
19 and the variable heavy chain sequence of SEQ ID NO;
20, and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) level is reduced, and whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
- 18, or SEQ ID NO;
-
28. A method of improving survivability or quality of life of a patient in need thereof having increased C reactive protein levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises a variable light sequence which is at least 95% identical to the variable heavy chain sequence of SEQ ID NO:
- 18 or 19 and a variable light chain sequence which is at least 95% identical to SEQ ID NO;
20 and whereby the patient'"'"'s serum C-reactive protein (“
CRP”
) level is reduced, and whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
- 18 or 19 and a variable light chain sequence which is at least 95% identical to SEQ ID NO;
-
29. A method of improving survivability or quality of life of a patient in need thereof having reduced serum albumin levels, comprising administering to the patient an anti-IL-6 antibody or antibody fragment, wherein said antibody comprises a variable light sequence which is at least 95% identical to the variable heavy chain sequence of SEQ ID NO:
- 18 or 19 and a variable light chain sequence which is at least 95% identical to SEQ ID NO;
20 and whereby the patient'"'"'s serum albumin level is increased, and whereby the administration of the anti-IL-6 antibody or antibody fragment results in improved survivability or quality of life in said patient.
- 18 or 19 and a variable light chain sequence which is at least 95% identical to SEQ ID NO;
Specification